Home > Riviste > Minerva Urology and Nephrology > Fascicoli precedenti > Minerva Urologica e Nefrologica 2018 April;70(2) > Minerva Urologica e Nefrologica 2018 April;70(2):126-36



Opzioni di pubblicazione
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca


Publication history
Per citare questo articolo


REVIEW   Free accessfree

Minerva Urologica e Nefrologica 2018 April;70(2):126-36

DOI: 10.23736/S0393-2249.17.03072-7


lingua: Inglese

Perioperative antithrombotic therapy in patients undergoing endoscopic urologic surgery: where do we stand with current literature?

Richard NASPRO 1 , Lori B. LERNER 2, Roberta ROSSINI 3, Michele MANICA 1, Henry H. WOO 4, Ross J. CALOPEDOS 4, Cecilia M. CRACCO 5, Cesare M. SCOFFONE 5, Thomas R. HERRMANN 6, Jean J. de la ROSETTE 7, Jean-Nicolas CORNU 8, Luigi F. DA POZZO 1

1 Department of Urology, ASST Papa Giovanni XXIII, Bergamo, Italy; 2 Section of Urology, Veteran Affairs Boston Healthcare System, Boston, MA, USA; 3 Department of Emergency and Critical Care, S. Croce e Carle Hospital, Cuneo, Italy; 4 Sydney Adventist Hospital Clinical School, University of Sydney, Wahroonga, Australia; 5 Department of Urology, Cottolengo Hospital, Turin, Italy; 6 Department of Urology and Urooncology, Hannover Medical School, Hannover, Germany; 7 Department of Urology, AMC University Hospital, Amsterdam, The Netherlands; 8 Service of Urology, Rouen University Hospital, Rouen, France


The number of patients on chronic anticoagulant or antiplatelet therapy requiring endoscopic urological surgery is increasing worldwide. Therefore, there is a strong demand to standardize the perioperative treatment of this cohort of patients, both from a surgical and cardiological point of view, balancing the risks of bleeding versus thrombosis, and the important possible clinical and medical legal repercussions therein. Although literature is scarce and the quality of evidence quite low, in line with other surgical specialties, guidelines and recommendations for the management of urological patients have begun to emerge. The aim of this review is to analyze current available literature and evidence on the most common endoscopic procedures performed in this high-risk group of patients, focusing on the perioperative management. In particular, to analyze the most frequently performed endoscopic procedures for the treatment of benign prostate enlargement (transurethral resection of the prostate, Thulium, Holmium and greenlight laser prostatectomy), bladder cancer (transurethral resection of the bladder), upper urinary tract urothelial cancer, and nephrolithiasis. Despite the lack of randomized studies, regardless of individual patient considerations, studies would support continuation of acetylsalicylic acid, which is recommended by cardiologists, in patients with intermediate/high risk of coronary thrombosis. In contrast, multiple studies found that bridging with light weight molecular weight heparin can potentially lead to more bleeding than continuation of the anticoagulant(s) and antiplatelet therapy, and caution with bridging is advised. All urologists should familiarize themselves with emerging guidelines and recommendations, and always be prepared to discuss specific cases or scenarios in a dedicated multidisciplinary team.

KEY WORDS: Urologic surgical procedures - Anticoagulants - Stents - Endoscopy - Aspirin

inizio pagina